000134830 001__ 134830
000134830 005__ 20240711085510.0
000134830 0247_ $$2doi$$a10.1007/s43393-024-00241-3
000134830 0248_ $$2sideral$$a138329
000134830 037__ $$aART-2024-138329
000134830 041__ $$aeng
000134830 100__ $$aNaik, Azza Silotry
000134830 245__ $$aProtease hydrolysed brewers’ spent grain bioactive extracts for applications in human health
000134830 260__ $$c2024
000134830 5060_ $$aAccess copy available to the general public$$fUnrestricted
000134830 5203_ $$aAbout 39 million tons of Brewer’s spent grain (BSG), the main by-product of beer manufacturing, are produced annually and is used for low value applications. To valorise this rich bioresource, the present work entails bioprocessing of BSG with various proteases (Novozymes) at two different concentrations (4% and 9%) to solubilise protein, carbohydrate and polyphenols from the grain and evaluate its effect on gut and brain health. The results show the highest (p < 0.05) FRAP (Ferric Reducing Antioxidant Power) based antioxidant activity was obtained for Pro 5 (4%: 108.10 ± 4.17 µmole Trolox Equivalence (TE)/g protein, 18.06 ± 0.70 µmole TE/g d.w., which was 3.6 times higher than untreated control extracts. The highest DPPH (1,1-diphenyl-2-picrylhydrazyl) scavenging activity was obtained for the same extract (Pro 5 at 4%: 0.118 ± 0.006 µg AAE/mg d.w., 9%: 0.110 ± 0.006 µg AAE/mg d.w). Proximate composition showed this extract to contain the highest concentration of proteins at 21.66% ± 2.71, and color analysis showed the same Pro 5 (4%) extract to be the darkest (L*53.73) indicating the possible presence of dark polyphenols. Anticancer screening showed Control and Pro 1 to possess cytotoxic effect against colon cancer cells with IC50 of 3.2 and 13.91 mg/mL, respectively. No significant activity was noted against the brain cancer cell line. Thus anti-colon cancer activity of BSG extracts highlights its potential in gut health. The observed bioactivity resulted from a combination of peptides, carbohydrates and polyphenolic compounds in the extract and warrants further characterisation for targeted nutraceutical applications.
000134830 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000134830 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000134830 700__ $$aBrugiere, Mila
000134830 700__ $$aDunne, Kevin
000134830 700__ $$aSorohan, Michael
000134830 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa, Laura$$uUniversidad de Zaragoza
000134830 700__ $$aJaved, Bilal
000134830 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000134830 773__ $$g4 (2024), 1062–1075$$pSyst. microbiol. biomanuf.$$tSystems microbiology and biomanufacturing$$x2662-7655
000134830 8564_ $$s2192049$$uhttps://zaguan.unizar.es/record/134830/files/texto_completo.pdf$$yVersión publicada
000134830 8564_ $$s1904962$$uhttps://zaguan.unizar.es/record/134830/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000134830 909CO $$ooai:zaguan.unizar.es:134830$$particulos$$pdriver
000134830 951__ $$a2024-07-11-08:52:26
000134830 980__ $$aARTICLE